Toxicity and efficacy of Palbociclib with endocrine therapy of physician’s choice in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: A single centre experience

Authors :: Stephen R. D. Johnston
Belinda Kingston
Kabir Mohammed
Nicolò Matteo Luca Battisti
Source :: Journal of Clinical Oncology. 36:e13039-e13039
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e13039Background: Palbociclib is approved in the UK in first line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Program (CAP) allowed patient...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Advanced breast
Endocrine therapy
HER2 negative
Cancer
Palbociclib
medicine.disease
humanities
Hormone receptor
Internal medicine
Toxicity
medicine
Line (text file)
skin and connective tissue diseases
business

Full Text Access

Tools